KANEKA
31.3.2023 16:10:30 CEST | Business Wire | Press release
Kaneka Corporation (Headquarters: Minato-ku, Tokyo; President: Minoru Tanaka; hereinafter "Kaneka"), Bacchus Bio innovation Co., Ltd (Headquarters: Kobe-city, Hyogo; President: Mikio Tanji; hereinafter "Bacchus"), JGC Holdings Corporation (Headquarters: Yokohama-city Kanagawa; Chairman and CEO: Masayuki Sato; hereinafter "JGC HD"), and Shimadzu Corporation (Headquarters: Kyoto-city, Kyoto; President: Yasunori Yamamoto; hereinafter "Shimadzu") have announced that the proposal of a joint project, “Development of Polymer Synthesis Technology by microorganisms using CO2 as direct raw material (hereinafter referred to as ‘the Project’)” had been selected by the "Green Innovation Fund Project*1 / Promotion of Carbon Recycling Using CO2 from Biomanufacturing Technology as a Direct Raw Material” as a planned implementation sponsored by the New Energy and Industrial Technology Development Organization (NEDO).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230331005155/en/
(Figure 1) Recycling-oriented Biomanufacturing Technology (Graphic: Business Wire)
This project will contribute to the realization of carbon recycling in the "Green Growth Strategy Through Achieving Carbon Neutrality in 2050" formulated by the Ministry of Economy, Trade and Industry with related ministries and agencies on December 25, 2020 (revised on June 18, 2021). The goal of the project is to realize recycling-oriented biomanufacturing technology that does not depend on fossil resources by developing microorganisms that produce biodegradable polymers from CO2 and developing production process technology, combining the knowledge and technology that the four companies have cultivated over the years.
During the project period (FY2023 to FY2030), the following three themes will be addressed.
- Establishment of a gas fermentation biofoundry*2 using CO2 as a raw material (Bacchus and Shimadzu)
- Development and improvement of biopolymer-producing microorganisms (Kaneka)
- Development and demonstration of production technology using microorganisms capable of producing substances from CO2 (Kaneka, JGC HD, Shimadzu)
[ Kaneka ] https://www.kaneka.co.jp/en/
Kaneka is the first company in the world to successfully commercialize KANEKA Biodegradable Polymer Green PlanetTM ("Green Planet"), which is produced by microorganisms from vegetable oil and other raw materials. In this project, based on the synthetic microbiology and polymer production, processing technologies it has cultivated to date, Kaneka will develop new microorganisms that produce Green Planet directly from CO2, and will also launch a semi-commercial plant to conduct production demonstration for Green Planet industrialization. In addition, we will lead this project as the managing company.
[ Bacchus ] https://www.b2i.co.jp/
Bacchus is a data-driven biofoundry company. Bacchus aims to drastically shorten the breeding time of smart cells*3 by upgrading the breeding platform consolidating its proprietary technologies. By utilizing its own digital technology, Bacchus will design cells optimized for gas fermentation and create a variety of species. In addition, they will introduce and utilize data from a high-throughput evaluation system jointly developed with Shimadzu, and aim to build an "Integrated Biofoundry*4" that will provide one-stop service from microbial breeding to process development with JGC HD.
[ JGC HD ] https://www.jgc.com/en/
JGC HD has a profound knowledge of the safe gas handling of gases including hydrogen gas and process scale-up cultivated through its EPC (Engineering, Procurement, and Construction) business in the oil and gas fields, as well as in optimized culture tank design technology in the life science field. In this project, JGC HD will develop and scale-up a safe handling system for mixed gases containing CO2, H2, and O2 and a highly efficient gas fermentation process in addition to establishing an “Integrated Biofoundry” with Bacchus which will provide a one-stop service from microbial breeding to process development.
[ Shimadzu ] https://www.shimadzu.com/
Shimadzu, with the aim of solving social issues, has accumulated a variety of know-how by providing analytical measurement and robotics technologies to a wide range of fields and data analysis technologies using AI-based systems. In this project, Shimadzu will work on the development of high-speed productivity evaluation technology, which is indispensable for the construction of a biofoundry. Shimadzu will also develop an evaluation system to measure gas fermentation in the semi-commercial plant which is to be constructed as part of the project and support safe and highly efficient fermentation.
*1. A project to support companies and others working on management issues toward Japan's "Carbon Neutrality in 2050," from R&D and demonstration to social implementation by FY2030. The program covers 14 fields: transportation/manufacturing-related industries including carbon recycling/materials industries, energy-related industries, and home/office-related industries.
*2. Biofoundry: Microorganism development platform that creates microorganisms with designed functions to efficiently produce useful substances
*3. Smart cell: A cell that is highly designed and has an enhanced ability to efficiently produce the desired substance
*4. Integrated Biofoundry: A one-stop biomanufacturing platform that provides everything from microbial breeding to process development
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230331005155/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
OpenRouter Raises $113 Million CapitalG-led Series B as Weekly Volume Explodes to 25T Tokens26.5.2026 15:15:00 CEST | Press release
NVentures, ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures join CapitalG, a16z, Menlo Ventures, and others in backing the high-growth AI infrastructure startup OpenRouter, the AI model exchange, today announced a $113 million Series B led by Alphabet’s independent growth fund, CapitalG, with participation from investors including NVentures (NVIDIA’s venture capital arm), ServiceNow Ventures, MongoDB Ventures, Snowflake Ventures, Databricks Ventures, alongside existing investors including Andreessen Horowitz and Menlo Ventures. OpenRouter’s volume has surged to 25 trillion tokens per week (100 trillion tokens per month), representing a 5X increase from the 5 trillion tokens processed per week just six months ago. The explosion in token demand illustrates how quickly enterprises are deploying agents and scaling AI across multiple models and providers. OpenRouter’s infrastructure manages and optimizes inference and provides access to 400+ models across leadi
Xsolla Expands Its Community Management Tools for Creators, Community Leaders, and Resellers26.5.2026 15:00:00 CEST | Press release
Xsolla Adds New Features For Creators, Community Leader Experience, And Distinct Channels For Emerging Markets Xsolla, a leading global video game commerce company, today announced three simultaneous expansions of its community management tools and products. As the creator economy continues to reshape how games are discovered and the industry accelerates its shift toward direct-to-consumer commerce, Xsolla is building on its community management tools for creators, community leaders, and emerging markets, and will showcase them at TwitchCon Rotterdam later this month. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260526596720/en/ Graphic: Xsolla The games industry has never had a shortage of people who drive player acquisition, loyalty, and commerce; it's had a shortage of infrastructure that recognizes them. Creators stream it. Community leaders build a culture around it. Local resellers get it into the hands of players in
Biocytogen Launches AI-Powered RenSuper™ Platform and Industry-First Fully Automated Antibody Discovery Infrastructure26.5.2026 14:00:00 CEST | Press release
Biocytogen today announced the launch of RenSuper Workstation, a next-generation AI-powered antibody discovery platform providing off-the-shelf access to a large-scale, experimentally validated library of fully human therapeutic antibody sequences, together with the RenSuper High-Throughput Antibody Manufacturing Automation Center, a fully automated infrastructure designed to accelerate antibody validation and production. Built on Biocytogen’s proprietary RenMice® platforms, RenSuper establishes a closed-loop antibody discovery engine combining in vivo immune repertoires, AI-driven candidate selection, automated experimental validation, and scalable manufacturing infrastructure. The platform supports the discovery and development of monoclonal antibodies, bispecifics, multispecifics, antibody-drug conjugates (ADCs), VHHs, and other advanced therapeutic modalities, significantly reducing the time and risk associated with antibody discovery. RenSuper Workstation: AI-Powered One-Click Tar
ViaLase Announces Global Commercial Introduction of the FLIGHT Procedure26.5.2026 14:00:00 CEST | Press release
First commercial femtosecond laser image-guided, high precision trabeculotomy (FLIGHT) treatments mark a new era in interventional glaucoma; one where precision, safety, and the patient experience define the new standard of care ViaLase, Inc., a commercial stage medical technology company pioneering incision-free, laser-based solutions for glaucoma, today announced the successful completion of the first commercial FLIGHT procedures performed at Centre for Sight in London by Sheraz Daya, MD, and Gus Gazzard, MD, and at Breyer, Kaymak & Klabe Augenchirurgie in Düsseldorf, Germany, by Karsten Klabe, MD. The first commercial FLIGHT procedures were performed using the ViaLuxe® Laser System to deliver an incision-free, image-guided femtosecond laser treatment designed to create precise channels through the trabecular meshwork to restore aqueous outflow and reduce intraocular pressure in patients with open-angle glaucoma. “Centre for Sight has always been committed to bringing meaningful inno
BioIVT to Spotlight ADME-Tox Expertise and Solutions at Summer 2026 Events26.5.2026 14:00:00 CEST | Press release
Company will demonstrate how high-quality, well-characterized biospecimens are critical to the success of both new approach methodologies (NAMs) and traditional studies BioIVT, the leading biospecimen solutions provider and global research partner for drug and diagnostic development, today announced it will showcase its broad portfolio of ADME-Tox solutions and research expertise at several leading industry events, including the 2026 MPS World Summit and the ISSX 16th European Meeting. The MPS World Summit takes place May 26-May 29, 2026, in Washington, D.C. BioIVT colleagues will be available at booth #115 to discuss research questions and needs, including preparation, handling, and utilization of the high-quality tissues and cells needed for microphysiological systems (MPS), as well as conducting ADME studies and bioanalysis. BioIVT offers an extensive range of control and disease state biospecimens, including SPHEROID CERTIFIED™ Hepatocytes as well as advanced HEPATOPAC® co-cultures
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom